Pancreatic cancer risk predicted from disease trajectories using deep learning
Placido, D.; Yuan, B.; Hu, J. X.; Haue, A. D.; Yuan, C.; Kim, J.; Umeton, R.; Antell, G.; Chowdhury, A.; Franz, A.; Brais, L.; Andrews, E.; Regev, A.; Kraft, P.; Wolpin, B. M.; Rosenthal, M.; Brunak, S.; Sander, C.
Show abstract
Pancreatic cancer is an aggressive disease that typically presents late with poor patient outcomes. There is a pronounced medical need for early detection of pancreatic cancer, which can be addressed by identifying high-risk populations. Here we apply artificial intelligence (AI) methods to a dataset of 6 million patient records with 24,000 pancreatic cancer cases in the Danish National Patient Registry (DNPR) and, for comparison, a dataset of three million records with 3,900 pancreatic cancer cases in the United States Department of Veterans Affairs (US-VA) healthcare system. In contrast to existing methods that do not use temporal information, we explicitly train machine learning models on the time sequence of diseases in patient clinical histories and test the ability to predict cancer occurrence in time intervals of 3 to 60 months after risk assessment. For cancer occurrence within 36 months, the performance of the best model (AUROC=0.88, DNPR), trained and tested on disease trajectories, exceeds that of a model without longitudinal information (AUROC=0.85, DNPR). Performance decreases when disease events within a 3 month window before cancer diagnosis are excluded from training (AUROC[3m]=0.83). Independent training and testing on the US-VA dataset reaches comparable performance (AUROC=0.78, AUROC[3m]=0.76). These results raise the state-of-the-art level of performance of cancer risk prediction on real-world data sets and provide support for the design of prediction-surveillance programs based on risk assessment in a large population followed by affordable surveillance of a relatively small number of patients at highest risk. Use of AI on real-world clinical records has the potential to shift focus from treatment of late-stage to early-stage cancer, benefiting patients by improving lifespan and quality of life.
Matching journals
The top 6 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- ELISL: Early-Late Integrated Synthetic Lethality Prediction in Cancer 93%
- ECMarker: Interpretable machine learning model identifies gene expression biomarkers predicting clinical outcomes and reveals molecular mechanisms of human disease in early stages 93%
- Using Cancer Profiles to Identify Synthetic Lethal Therapeutic Targets and Predictive Biomarkers in Cancer Gene Dependency Data 92%
Similar papers in this journal
- Pancreatic cancer symptom trajectories from Danish registry data and free text in electronic health records 95%
- Disentangling the relationship between cancer mortality and COVID-19 93%
- Risk of Second Primary Cancers After a Diagnosis of First Primary Cancer: A Pan-Cancer Analysis and Mendelian Randomization Study 91%
Similar papers in this journal
Similar papers in this journal
- Deep representation learning for clustering longitudinal survival data from electronic health records 94%
- Machine learning-based tissue of origin classification for cancer of unknown primary diagnostics using genome-wide mutation features 92%
- Uncovering interpretable potential confounders in electronic medical records 92%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.